Arrivent Biopharma Inc (AVBP) — 13F Filings Explorer (Q2 2026)

AVBP ranks #3540 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

AVBP is a top-conviction position for General Catalyst Group Management, LLC — at 27.6% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in AVBP belongs to Montanova Capital, LLC, but the position matters far more to General Catalyst Group Management, LLC, who has 27.6% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Versant Capital Management, Inc has added to its AVBP position for two straight quarters, increasing it by $11.7K to reach $21.5K today.

AVBP is down 0.8% today, but institutions show net buying of $224.4M this quarter — a divergence between today's price move and the underlying institutional flow.

AVBP reported a net loss of $166.3M in its latest fiscal year.

• Not yet profitable — net loss of $166.3M in the latest fiscal year
• Net income declined year over year, from -$80.5M to -$166.3M
• Operating cash flow was negative, using $160.6M in cash
• Current ratio of 12.83x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.08x equity — within a conventional range